Inotersen (Tegsedi) is a 20-mer PS ASO gapmer that was approved in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) (Table 2), a rare genetic disorder that causes misfolding of transthyretin (TTR) protein. Here, TTR is linked to familial amyloid neuropathy.